The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2023 | ESMO 2023 highlights: advances in EGFR+ lung cancer second-line therapy
Crispin Hiley, PhD, UCL Cancer Institute, London, UK, shares his highlights from ESMO 2023, spotlighting the exciting progress in second-line treatment for EGFR mutation-positive lung cancer patients who have progressed on osimertinib or third-generation tyrosine kinase inhibitors (TKIs). These patients face a significant unmet need, and the development of an effective second-line systemic combination offers hope and improved outcomes, especially for those who aren’t suitable for metastasis-directed therapy. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
